ClinicalTrials.gg
RecruitingNCT07232602Updated Oct 2, 2026

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

A Phase 1/2 interventional study of MK-3120 and EV in Bladder Cancer, sponsored by Merck Sharp & Dohme LLC. Recruiting at 17 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 2, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Urinary Bladder Neoplasms by Merck & Co., Inc — 5 open to participants now, 9 under way, 5 of them phase 3. Urinary Bladder Neoplasms · Merck & Co., Inc.

Planned enrollment
13th of 17
55 · median 374
Started
2026
with 2 others
Phase 1/2
3 of 17
2 open now
Registered
15th of 17
by date

Among the 17 studies in Urinary Bladder Neoplasms by Merck & Co., Inc, this one is the 13th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 1/2, and was the 15th registered.

Urinary Bladder Neoplasms

1,801 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

5 of the 17 studies in Urinary Bladder Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 337 Urinary Bladder Neoplasms studies recruiting now, 257 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Urinary Bladder Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with pembrolizumab.

The goals of this study are to learn about:

  • The safety of the study treatment when given with standard treatment and if people tolerate it
  • The number of people who have the cancer respond (cancer gets smaller or goes away) with the new study treatment when given with standard treatment.
Read the detailed description

This is a substudy of the master protocol MK-3475-U04 (KEYMAKER-U04)

03

Conditions studied

  • Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has documented urothelial carcinoma (UC) that is locally advanced and unresectable or
  • Must provide a newly obtained or sample (core or excisional biopsy)
  • Must not have received prior systemic therapy for locally advanced or metastatic UC
  • If infected with (HIV), has well controlled HIV on antiretroviral therapy
  • If positive for surface antigen, has received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and has undetectable HBV viral load before randomization
  • If participant has a history of virus (HCV), has undetectable HCV viral load before randomization

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing
  • Has active keratitis or corneal ulcerations
  • Has active inflammatory bowel disease requiring medication, or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within the 6 months preceding study intervention
  • Has a history of uncontrolled diabetes
  • Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
  • Has active disease that has required systemic treatment in the past 2 years
  • Has known additional that is progressing or has required active treatment within the past 2 years
  • Has known active central nervous system and/or carcinomatous meningitis
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required , or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • If infected with , has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has concurrent active and infection
  • Has a history of stem cell/solid organ transplant
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Arm A: MK-3120 + Enfortumab Vedotin (EV) + Pembrolizumab

    Participants will receive MK-3120 administered intravenously on Day 1 and Day 8 of each 3-week cycle and EV administered intravenously on Day 1 and Day 8 of each 3-week cycle until documented disease progression or any other discontinuation criterion is met and Pembrolizumab 200 mg administered intravenously on Day 1 of each 3-week cycle for up to 35 cycles (\~2 years).

    Drug: MK-3120 · Drug: EV · Biological: Pembrolizumab · Drug: Rescue Medication

Interventions

  • Administered via intravenous (IV) infusion on day 1 and day 8 of each 3-week cycle

  • DrugEV

    Administered via IV infusion on day 1 and day 8 of each 3-week cycle

    Also known as: AGS 22M6E, AGS-22CE

  • BiologicalPembrolizumab

    Administered via IV infusion on day 1 of each 3-week cycle

    Also known as: MK-3475, KEYTRUDA®

  • DrugRescue Medication

    Participants receive rescue medication at the investigator's discretion, per approved product label. Recommended rescue medication is Granulocyte Colony-Stimulating Factor (G-CSF).

This study also gives Enfortumab vedotin. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.

    Time frame: Up to approximately 27 months

  2. Number of Participants Who Experience a Dose Limiting Toxicity (DLT)

    DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next treatment. The number of participants who experience a DLT as Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 will be presented.

    Time frame: Up to approximately 21 days

  3. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 24 months

  4. Objective Response Rate (ORR) as Assessed by Investigator

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Investigator will be presented.

    Time frame: Up to approximately 58 months

Secondary outcomes

  1. Duration of Response (DOR) as Assessed by Investigator

    For participants who demonstrate a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by investigator will be presented.

    Time frame: Up to approximately 58 months

  2. Serum Maximum Concentration (Cmax) of MK-3120 Antibody-Drug Conjugate (ADC)

    Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of MK-3120 ADC.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  3. Serum Trough Concentration (Ctrough) of MK-3120 ADC

    Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of MK-3120 ADC.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  4. Serum Cmax of MK-3120 Total Antibodies (TAb)

    Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of MK-3120 TAb.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  5. Serum Ctrough of MK-3120 TAb

    Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of MK-3120 TAb.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  6. Plasma Cmax of MK-3120 Free Payload

    Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of MK-3120 Free Payload.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  7. Plasma Ctrough of MK-3120 Free Payload

    Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of MK-3120 Free Payload.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  8. Serum Cmax of EV ADC

    Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of EV ADC.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  9. Serum Ctrough of EV ADC

    Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of EV ADC.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  10. Serum Cmax of EV TAb

    Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of Enfortumab Vedotin (EV) TAb.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  11. Serum Ctrough of EV TAb

    Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of EV TAb.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  12. Plasma Cmax of EV Free Payload

    Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of Enfortumab Vedotin (EV) Free Payload.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

  13. Plasma Ctrough of EV Free Payload

    Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of EV Free Payload.

    Time frame: Predose and at designated time points post-dose (up to approximately 24 months)

07

Study locations

17 of 17 sites recruiting
  • UCSF Medical Center at Mission Bay ( Site 5044)
    San Francisco, California 94158, United States
    Recruiting
    • Study Coordinator · Contact415-699-7286
  • University of Chicago Medical Center ( Site 5037)
    Chicago, Illinois 60637, United States
    Recruiting
    • Study Coordinator · Contact773-702-1000
  • Memorial Sloan Kettering Cancer Center ( Site 5031)
    New York, New York 10065, United States
    Recruiting
    • Study Coordinator · Contact347-798-9213
  • Cleveland Clinic Taussig Cancer ( Site 5036)
    Cleveland, Ohio 44195, United States
    Recruiting
    • Study Coordinator · Contact216-444-8311
  • Huntsman Cancer Institute ( Site 5041)
    Salt Lake City, Utah 84112-5550, United States
    Recruiting
    • Study Coordinator · Contact801-585-0155
  • Fundación Arturo López Pérez ( Site 5151)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact+56956075934
  • CHU de Bordeaux Hop St ANDRE ( Site 5607)
    Bordeaux, Gironde 33075, France
    Recruiting
    • Study Coordinator · Contact+33556794708
  • Rambam Health Care Campus ( Site 5501)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact+97247772688
  • Rabin Medical Center ( Site 5504)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact+97239377377
  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 5302)
    Amsterdam, North Holland 1066 CX, Netherlands
    Recruiting
    • Study Coordinator · Contact+31205129111
  • Erasmus MC ( Site 5303)
    Rotterdam, South Holland 3015 GD, Netherlands
    Recruiting
    • Study Coordinator · Contact+31107040704
  • Severance Hospital, Yonsei University Health System ( Site 5903)
    Seoul, 03722, South Korea
    Recruiting
    • Study Coordinator · Contact+8215887757
  • Asan Medical Center ( Site 5901)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+8216887575
  • Samsung Medical Center ( Site 5902)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact+8215993114
  • Hospital Universitari Vall de Hebron ( Site 5767)
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact+34932543450
  • Hospital Clinico San Carlos ( Site 5765)
    Madrid, 28040, Spain
    Recruiting
    • Study Coordinator · Contact+34913303546
  • St Bartholomew s Hospital ( Site 5206)
    London, London, City of EC1A 7BE, United Kingdom
    Recruiting
    • Study Coordinator · Contact+442078228498
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jul 2031, 64 months after the start.

Of 39 industry-sponsored phase 1/2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 74. This study's planned 64 months is above that.

Counting every sponsor, half of 67 studies reached it within 52 months; a quarter within 35 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartActual
Feb 9, 2026
Primary completionEst.
Jul 8, 2031
CompletionEst.
Jul 8, 2031
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 United States, 1 Chile)
  • Memorial Sloan Kettering Cancer Center ( Site 5031) · New York, United States
  • Fundación Arturo López Pérez ( Site 5151) · Santiago, Chile
Show 1 removed
  • FALP ( Site 5151) · Santiago, Chile
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    2 sites added, 1 site removed
    Show 2 added (1 United States, 1 Chile)
    • Memorial Sloan Kettering Cancer Center ( Site 5031) · New York, United States
    • Fundación Arturo López Pérez ( Site 5151) · Santiago, Chile
    Show 1 removed
    • FALP ( Site 5151) · Santiago, Chile
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07232602
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Feb 9, 2026
Primary completion
Jul 8, 2031 (estimated)
Completion
Jul 8, 2031 (estimated)
Last update
Oct 2, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-nectin-4 Antibody-drug Conjugate MK-3120

Start the discussion